ACCC SEEKS BIGGER FINE AGAINST MAKERS OF NUROFEN

ACCC SEEKS BIGGER FINE AGAINST MAKERS OF NUROFEN

RECKITT Benckiser's legal headache has taken another turn after the consumer watchdog appealed an 'inadequate' fine of $1.7 million for misleading customers.

The Australian Competition and Consumer Commission (ACCC) has filed a Notice of Appeal from the Federal Court's decision against the pharmaceutical company for contravening the Australian Consumer Law.

Last December, the court found that Reckitt Benckiser made deceptive claims on its website and product packaging that Nurofen Specific Pain products were formulated to treat particular types of pain.

While each of the varieties of back pain, period pain, migraines and tension headaches all contained the company's standard ibuprofen lysine 342mg but sold for almost double the price.

The ACCC argued that the active ingredient is used for a wide variety of conditions and is no more effective at treating the pain of described on its packaging than any other Nurofen Specific Pain products.

Reckitt Benckiser was ordered to pay penalties totalling $1.7 million last month, despite a recommendation for a $6 million fine to send a strong deterrence message. The court found that although the packaging was designed for profit, the product didn't cause any physical harm.

ACCC chairman Rod Sims says the penalty was inadequate considering the longstanding and widespread nature of the conduct and significant profit made.

"The ACCC will submit to the Full Court of the Federal Court that $1.7 million in penalties imposed on a company the size of Reckitt Benckiser does not act as an adequate deterrent and might be viewed as simply a cost of doing business," Sims says.

"This is particularly the case when the judge found that Reckitt Benckiser had made many millions in profits from sales of 5.9 million units of these products at around 8500 outlets during the relevant period."

 

Enjoyed this article?

Don't miss out on the knowledge and insights to be gained from our daily news and features.

Subscribe today to unlock unlimited access to in-depth business coverage, expert analysis, and exclusive content across all devices.

Support independent journalism and stay informed with stories that matter to you.

Subscribe now and get 50% off your first year!

Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

Former IPO hopeful Limepay acquired by Spenda at a fraction of the $43.5m invested

Former IPO hopeful Limepay acquired by Spenda at a fraction of the $43.5m invested

White-label buy-now pay-later (BNPL) company Limepay may have ...

Melbourne construction safety software group HammerTech receives $105m investment for growth

Melbourne construction safety software group HammerTech receives $105m investment for growth

HammerTech, a Melbourne-headquartered safety intelligence software ...

Here’s how to make sure Indigenous businesses keep thriving across a wide range of industries

Here’s how to make sure Indigenous businesses keep thriving across a wide range of industries

When discussing the creativity and ingenuity of Indigenous people, ...

Brisbane-based IT consultancy Exent acquired by Atturra for up to $8m

Brisbane-based IT consultancy Exent acquired by Atturra for up to $8m

Founder-led IT consultancy Exent is set to join the growing portfol...